Pub Date : 2024-05-20eCollection Date: 2024-01-01DOI: 10.18632/oncoscience.602
Gregory L Guzik, Ankit Mangla
{"title":"Primary hepatic angiosarcoma: Treatment options for a rare tumor.","authors":"Gregory L Guzik, Ankit Mangla","doi":"10.18632/oncoscience.602","DOIUrl":"10.18632/oncoscience.602","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"47-48"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-20eCollection Date: 2024-01-01DOI: 10.18632/oncoscience.603
Richard L J Qiu, Chih-Wei Chang, Xiaofeng Yang
{"title":"Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer.","authors":"Richard L J Qiu, Chih-Wei Chang, Xiaofeng Yang","doi":"10.18632/oncoscience.603","DOIUrl":"10.18632/oncoscience.603","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"49-50"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-06eCollection Date: 2024-01-01DOI: 10.18632/oncoscience.600
Xiaoling Li, Ping Mu
{"title":"Restoring our ubiquitination machinery to overcome resistance in cancer therapy.","authors":"Xiaoling Li, Ping Mu","doi":"10.18632/oncoscience.600","DOIUrl":"10.18632/oncoscience.600","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"43-44"},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-25DOI: 10.18632/oncoscience.599
J. K. Nag, Amnon Hoffman, Chaim Gilon, Beatrice Uziely, R. Bar-Shavit
{"title":"PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs","authors":"J. K. Nag, Amnon Hoffman, Chaim Gilon, Beatrice Uziely, R. Bar-Shavit","doi":"10.18632/oncoscience.599","DOIUrl":"https://doi.org/10.18632/oncoscience.599","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"18 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-22DOI: 10.18632/oncoscience.597
Rafael Parra-Medina
{"title":"Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding","authors":"Rafael Parra-Medina","doi":"10.18632/oncoscience.597","DOIUrl":"https://doi.org/10.18632/oncoscience.597","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 24","pages":"34 - 35"},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140674016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-09eCollection Date: 2024-01-01DOI: 10.18632/oncoscience.595
Paul Dent
{"title":"A very long and winding road: developing novel therapeutics for metastatic tumors.","authors":"Paul Dent","doi":"10.18632/oncoscience.595","DOIUrl":"https://doi.org/10.18632/oncoscience.595","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"32-33"},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10856472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-03eCollection Date: 2024-01-01DOI: 10.18632/oncoscience.593
Mikhail V Blagosklonny
In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.
{"title":"My battle with cancer. Part 1.","authors":"Mikhail V Blagosklonny","doi":"10.18632/oncoscience.593","DOIUrl":"10.18632/oncoscience.593","url":null,"abstract":"<p><p>In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139379085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-30eCollection Date: 2023-01-01DOI: 10.18632/oncoscience.592
R Daniel Bonfil, Ghaith Al-Eyd
During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies. The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. Here, we discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. The advances achieved in the molecular characterization of these types of liquid biopsies and their potential to predict recurrence, improve responses to certain treatments, and evaluate prognosis, in PCa patients, are highlighted herein. While there is currently full clinical validation for only one CTC-based and one ctDNA-based liquid biopsy for patients with metastatic castration-resistant PCa, the adoption of additional methods is anticipated as they undergo standardization and achieve analytical and clinical validation. Advantages and disadvantages of different blood-based liquid biopsy approaches in the context of PCa are outlined herein, while also considering potential synergies through combinatory strategies.
{"title":"Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.","authors":"R Daniel Bonfil, Ghaith Al-Eyd","doi":"10.18632/oncoscience.592","DOIUrl":"10.18632/oncoscience.592","url":null,"abstract":"<p><p>During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies. The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. Here, we discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. The advances achieved in the molecular characterization of these types of liquid biopsies and their potential to predict recurrence, improve responses to certain treatments, and evaluate prognosis, in PCa patients, are highlighted herein. While there is currently full clinical validation for only one CTC-based and one ctDNA-based liquid biopsy for patients with metastatic castration-resistant PCa, the adoption of additional methods is anticipated as they undergo standardization and achieve analytical and clinical validation. Advantages and disadvantages of different blood-based liquid biopsy approaches in the context of PCa are outlined herein, while also considering potential synergies through combinatory strategies.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"69-80"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号